These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6542450)

  • 1. Intermittent Iv homoharringtonine for the treatment of refractory epithelial carcinoma of the ovary: a phase II trial.
    Kavanagh JJ; Gershenson DM; Copeland LJ; Wharton JT; Rutledge FN; Krakoff IH
    Cancer Treat Rep; 1984 Dec; 68(12):1503-4. PubMed ID: 6542450
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas.
    Ajani JA; Dimery I; Chawla SP; Pinnamaneni K; Benjamin RS; Legha SS; Krakoff IH
    Cancer Treat Rep; 1986 Mar; 70(3):375-9. PubMed ID: 3955548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of homoharringtonine administered as a 5-day continuous infusion.
    Coonley CJ; Warrell RP; Young CW
    Cancer Treat Rep; 1983; 67(7-8):693-6. PubMed ID: 6871884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homoharringtonine: a phase I evaluation.
    Stewart JA; Krakoff IH
    Invest New Drugs; 1985; 3(3):279-86. PubMed ID: 4066221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study.
    Runge-Morris MA; Kies MS; Vokes E; Blough R; Weidner L; Knop R; Rowland K
    Invest New Drugs; 1989 Jul; 7(2-3):269-73. PubMed ID: 2793384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous-infusion vinblastine for treatment of refractory epithelial carcinoma of the ovary: a phase II trial.
    Kavanagh JJ; Wharton JT; Rutledge FN
    Cancer Treat Rep; 1984 Nov; 68(11):1417-8. PubMed ID: 6498856
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I trial of homoharringtonine.
    Neidhart JA; Young DC; Derocher D; Metz EN
    Cancer Treat Rep; 1983 Sep; 67(9):801-4. PubMed ID: 6883357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous-infusion spirogermanium for the treatment of refractory carcinoma of the ovary: a phase II trial.
    Kavanagh JJ; Saul PB; Copeland LJ; Gershenson DM; Krakoff IH
    Cancer Treat Rep; 1985 Jan; 69(1):139-40. PubMed ID: 3967257
    [No Abstract]   [Full Text] [Related]  

  • 9. Activity of two phase I drugs, homoharringtonine and tricyclic nucleotide, against surgical explants of human tumors in the 6-day subrenal capsule assay.
    Cobb WR; Bogden AE; Reich SD; Griffin TW; Kelton DE; LePage DJ
    Cancer Treat Rep; 1983 Feb; 67(2):173-8. PubMed ID: 6825125
    [No Abstract]   [Full Text] [Related]  

  • 10. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment.
    Chin Med J (Engl); 1976 Jul; 2(4):263-72. PubMed ID: 825360
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
    Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.
    Long HJ; Nelimark RA; Su JQ; Garneau SC; Levitt R; Goldberg RM; Poon MA; Kugler JW
    Gynecol Oncol; 1994 Aug; 54(2):180-3. PubMed ID: 8063243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Kerry Burke case and homoharringtonine.
    Sullivan J; Leyden M
    Med J Aust; 1984 Sep; 141(5):317-8. PubMed ID: 6381973
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
    Cowan JD; Surwit EA; Alberts DS; Boutselis JG; Neilan BA
    Cancer Treat Rep; 1986 Mar; 70(3):423-4. PubMed ID: 3955558
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B; Hansen HH; Høgdall C; Engelholm SA
    Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.
    Warrell RP; Coonley CJ; Gee TS
    J Clin Oncol; 1985 May; 3(5):617-21. PubMed ID: 3889229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase II trial with cisplatin in ovarian malignancies].
    Hosokawa T; Ito H; Tanaka T; Ichinoe K; Yamada Y; Suzuki M; Yajima A; Mori T; Takamizawa H; Sekiya S; Sakamoto S; Kawana T; Chen JT; Takada M; Takeuchi H; Akiya K; Hara S; Hara Y; Takeuchi S; Kanazawa K; Yoshizawa H; Tomoda Y; Ohta M; Hattori S; Yagami Y; Mizuno K; Koike K; Suzuoki Y; Totani R; Miwa T; Sugimoto O; Fujimoto A; Doi S; Tojo S; Iwasaki M; Sekiba K; Kohno I; Okazaki H; Ogawa S; Seto M; Komoto Y; Taki I; Tsukamoto N; Iwasaka T; Yamabe T; Nakajima H; Yoshida M
    Nihon Gan Chiryo Gakkai Shi; 1982 Feb; 17(1):31-40. PubMed ID: 6890088
    [No Abstract]   [Full Text] [Related]  

  • 20. Teniposide in refractory ovarian cancer: a phase II study.
    Sessa C; D'Incalci M; Landoni F; Colombo N; Mangioni C
    Cancer Treat Rep; 1984 May; 68(5):815-6. PubMed ID: 6722838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.